Collectively, our findings suggest that HDAC11 interacts with the IRF4/BLIMP1/MYC transcriptional network (24), which is critically dysregulated in myeloma genesis, and HDAC11 inhibition offers a potential therapeutic strategy for MM treatment. Here, MYC is linked to Miyoshi myopathy.